Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?

iShares U.S. Pharmaceuticals ETF offers a significantly higher dividend yield and lower volatility than State Street SPDR S&P Biotech ETF. While State Street SPDR S&P Biotech ETF delivered stronger 1-year returns, iShares U.S. Pharmaceuticals ETF showed much greater resilience with a shallower maximum drawdown.

The Motley Fool • Jun 17, 2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

ETF Trends • Jun 11, 2026

iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns

iShares U.S. Pharmaceuticals ETF provides more cost-efficient access to the healthcare sector with a lower expense ratio and a higher dividend yield Simplify Health Care ETF employs an active management strategy focused on innovation and donates its net profits to breast cancer research iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the past year while maintaining lower price volatility than its peer

The Motley Fool • Jun 10, 2026

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Zacks Investment Research • Jun 10, 2026

Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

Zacks Investment Research • Jun 9, 2026

US FDA to review AI-based tool to predict drug-related liver damage

The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for ​an artificial intelligence-based drug development tool designed to ‌help predict drug-induced liver injury.

Reuters • Jun 3, 2026

Healthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet

LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.

Zacks Investment Research • May 29, 2026

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway.

24/7 Wall Street • May 19, 2026

Trump to announce discount drug pricing expansion, White House official says

U.S. President Donald Trump will ‌announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his ​administration's pricing deal, on Monday, a White ​House official said.

Reuters • May 18, 2026

IHE: Healthcare Dashboard For May

The healthcare sector is undervalued based on historical averages, especially the healthcare equipment industry. iShares U.S. Pharmaceuticals ETF offers cap-weighted exposure to U.S. pharma, with 44% in Eli Lilly and Johnson & Johnson. Recent outperformance is notable: IHE is 27% ahead of XLV over the past 12 months.

Seeking Alpha • May 16, 2026